All drugs
Regorafenib (off Label)
Stivarga
Stage Phase 2
Sponsor Memorial Sloan Kettering (investigator)
Route oral
Modality small molecule
Class multi-kinase TKI
Mechanism VEGFR, KIT, RET and others (label class)
Target VEGFR1 to 3 (KDR, FLT1, FLT4) (TEC-0075)
Sources
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT02098538
Regorafenib in progressive R/M ACC, registry NCT02098538, results posted 09.10.2025 (registry; opened 2026-10-27): n 38; CR plus PR in 1 participant; serious AEs 14 of 38; best response and survival counts as posted.
Brief source A29
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT02098538
A Phase II Study of Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
Studies
Registry NCT02098538
Phase Phase 2
Status Completed
Enrollment 38
Start 2014-03
Primary completion 2024-11-07
Study completion 2024-11-07
Regorafenib
Dose not stated in source
Population progressive R/M ACC (n = 38)
Estimand Single arm
responders (CR or PR): 1 patients (of 38), results posted 09.10.2025
patients with serious adverse events: 14 patients (of 38), results posted